CN113607962B - Preservation solution for cTnI antibody coated magnetic beads and preparation method thereof - Google Patents
Preservation solution for cTnI antibody coated magnetic beads and preparation method thereof Download PDFInfo
- Publication number
- CN113607962B CN113607962B CN202110905348.5A CN202110905348A CN113607962B CN 113607962 B CN113607962 B CN 113607962B CN 202110905348 A CN202110905348 A CN 202110905348A CN 113607962 B CN113607962 B CN 113607962B
- Authority
- CN
- China
- Prior art keywords
- concentration
- preservation solution
- magnetic beads
- coated magnetic
- ctni antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003761 preservation solution Substances 0.000 title claims abstract description 59
- 239000011324 bead Substances 0.000 title claims abstract description 57
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000003223 protective agent Substances 0.000 claims abstract description 30
- 239000003755 preservative agent Substances 0.000 claims abstract description 28
- 230000002335 preservative effect Effects 0.000 claims abstract description 28
- 239000000337 buffer salt Substances 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 239000004094 surface-active agent Substances 0.000 claims abstract description 27
- 229940082500 cetostearyl alcohol Drugs 0.000 claims abstract description 22
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 22
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000002156 mixing Methods 0.000 claims description 43
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 38
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- 235000018102 proteins Nutrition 0.000 claims description 26
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 19
- 239000011592 zinc chloride Substances 0.000 claims description 19
- 235000005074 zinc chloride Nutrition 0.000 claims description 19
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 18
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 13
- 229940098773 bovine serum albumin Drugs 0.000 claims description 13
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 239000007983 Tris buffer Substances 0.000 claims description 9
- 239000001103 potassium chloride Substances 0.000 claims description 8
- 235000011164 potassium chloride Nutrition 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 239000007987 MES buffer Substances 0.000 claims description 2
- 239000007993 MOPS buffer Substances 0.000 claims description 2
- -1 PC300 Chemical compound 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 229960005091 chloramphenicol Drugs 0.000 claims description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 16
- 239000002904 solvent Substances 0.000 abstract description 9
- 238000003860 storage Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 238000000576 coating method Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 2
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The application discloses preservation solution of cTnI antibody coating magnetic bead, solvent is water, its characterized in that includes: a buffer salt; a protein; a surfactant; an inorganic salt; the protective agent is cetostearyl alcohol polyether-25; a preservative; the pH of the preservation solution is 7.0-8.0. The application also provides a preparation method of the preservation solution of the cTnI antibody coated magnetic beads. The preservation solution of the cTnI antibody coated magnetic beads can effectively improve the stability of the cTnI antibody coated magnetic beads in the storage and use processes; in particular, the addition of the protective agent can significantly improve the stability, sensitivity and linear gradient of the reagent. And the preservation solution of the cTnI antibody coated magnetic beads has the advantages of simple components, simple and convenient preparation, low cost and convenient realization of mass production.
Description
Technical Field
The application relates to the technical field of detection reagents, in particular to preservation solution of cTnI antibody coated magnetic beads and a preparation method thereof.
Background
Troponin (Tn) complex is composed of troponin I, troponin T and troponin C and is able to regulate muscle contraction. Cardiac troponin I (cardiactroponin I, cTnI) is an isoform of troponin I found in cardiomyocytes and has a high degree of myocardial specificity and can be used to identify clinical situations associated with myocardial and skeletal muscle injury.
Acute myocardial infarction (Acute Myocardial Infarction, AMI) is one of the major diseases that are currently life threatening in humans. When myocardial cells are damaged by myocardial infarction or ischemia, cTnI rapidly penetrates through myocardial cell membranes into blood. Therefore, in the early stage of onset, the cTnI and the change trend thereof in human blood can be rapidly, sensitively and accurately measured, and the method has important clinical significance for diagnosis and treatment of acute myocardial infarction.
The cTnI is used as a first-choice marker of myocardial injury, a common method for clinical detection at present is a chemiluminescent immunoassay method, and a magnetic particle chemiluminescent method is mainly adopted at present. The magnetic bead coated antibody plays an important role in the chemiluminescent detection reagent, so that the stability of the magnetic bead coated antibody lays a solid foundation for the high-quality chemiluminescent reagent.
At present, the stability of the magnetic bead coating antibody is improved, mainly starting from the optimization of the magnetic bead coating process or the optimization of the formula. However, the former is relatively complex in process, while the latter usually adopts commercial magnetic bead storage liquid, is relatively expensive, and has certain batch-to-batch difference to influence the reagent performance.
Therefore, how to provide a preservation solution for improving the use and storage stability of cTnI antibody coated magnetic beads, improving the storage stability, reducing the batch-to-batch difference and simultaneously reducing the cost is a technical problem to be solved by the person skilled in the art.
Disclosure of Invention
In order to solve the technical problems, a first object of the present invention is to provide a preservation solution of cTnI antibody coated magnetic beads; the second object of the invention is to provide a method for preparing preservation solution of the cTnI antibody-coated magnetic beads; the preservation solution of the cTnI antibody coated magnetic beads can effectively improve the stability of the cTnI antibody coated magnetic beads in the storage and use processes, and protective agents such as sugar, alcohol, lipid and the like are not required to be added; in particular, the addition of the protective agent can significantly improve the stability, sensitivity and linear gradient of the reagent. And the preservation solution of the cTnI antibody coated magnetic beads has the advantages of simple components, simple and convenient preparation, low cost and convenient realization of mass production.
The technical scheme provided by the invention is as follows:
a preservation solution of cTnI antibody coated magnetic beads, the solvent being water, comprising:
a buffer salt;
a protein;
a surfactant;
an inorganic salt;
the protective agent is cetostearyl alcohol polyether-25;
a preservative;
the pH of the preservation solution is 7.0-8.0.
Preferably, it comprises:
20-100mmol/L of buffer salt;
2-20g/L of protein;
0.5-5g/L of surfactant;
0.1 to 0.5mol/L of inorganic salt;
the protective agent is cetostearyl alcohol polyether-25-10 g/L;
0.5-5g/L preservative;
the pH of the preservation solution is 7.0-8.0.
Preferably, the buffer salt is specifically any one of Tris, MES, MOPS, HEPES; and/or the number of the groups of groups,
the concentration of the buffer salt is 50-60mmol/L.
Preferably, the protein is specifically any one or more of bovine serum albumin, casein, gelatin protein.
Preferably, the protein is bovine serum albumin, and the concentration of the bovine serum albumin is 10-15g/L.
Preferably, the surfactant is any one or more of triton x-100, triton x-405, tween 20 and tween 80; and/or the number of the groups of groups,
the concentration of the surfactant is 1-2g/L.
Preferably, the inorganic salt is specifically a combination of sodium chloride, magnesium chloride, zinc chloride; or the ionic salt is a combination of potassium chloride, magnesium chloride and zinc chloride; the concentration of sodium chloride is 0.1-0.3 mol/L; the concentration of magnesium chloride is 0.5-5mmol/L; the concentration of zinc chloride is 0.05-1mmol/L; the concentration of the potassium chloride is 0.1-0.3 mol/L.
Preferably, in the inorganic salt combination, the concentration of sodium chloride is 0.1-0.2 mol/L; the concentration of magnesium chloride is 2.5-5 mmol/L; the concentration of zinc chloride is 0.1-0.5 mmol/L; the concentration of the potassium chloride is 0.1-0.2 mol/L.
More preferably, the inorganic salt composition used is: sodium chloride 0.15mol/L, magnesium chloride 5mmol/L, zinc chloride 0.1mmol/L;
or 0.15mol/L of potassium chloride, 5mmol/L of magnesium chloride and 0.1mmol/L of zinc chloride;
or, 0.15mol/L of sodium chloride, 2.5mmol/L of magnesium chloride and 00.5mmol/L of zinc chloride;
or 0.15mol/L of potassium chloride, 2.5mmol/L of magnesium chloride and 00.5mmol/L of zinc chloride.
Preferably, the preservative is specifically any one or more of sodium azide, PC300, chloramphenicol and gentamicin; and/or the number of the groups of groups,
the concentration of the preservative is 1-2g/L.
Preferably, the preservation solution is pH-adjusted using an inorganic acid or an inorganic base. Among them, the inorganic acid is preferably hydrochloric acid, and the inorganic base is preferably sodium hydroxide.
A preparation method of preservation solution of cTnI antibody coated magnetic beads comprises the following steps:
respectively adding buffer salt, protein, surfactant, inorganic salt, cetostearyl alcohol polyether-25 serving as a protective agent and preservative into water, and uniformly mixing so that the concentration of the buffer salt is 20-100mmol/L and the concentration of the protein is 2-20g/L; the concentration of the surfactant is 0.5-5g/L; the concentration of the inorganic salt is 0.1-0.5mol/L; the concentration of the protecting agent cetostearyl alcohol polyether-25 is 1-10g/L, and the concentration of the preservative is 0.5-5g/L; and adjusting the pH to 7.0-8.0;
constant volume and filtering. According to the preparation method of the preservation solution of the cTnI antibody coated magnetic beads, which is provided by the application, the sequence of adding buffer salt, protein, surfactant, inorganic salt, preservative cetostearyl alcohol polyether-25 is not required, each substance is only required to be added independently and uniformly mixed, then the next is added, and finally, the pH value, the constant volume and the filtration are adjusted.
The preservation solution of the cTnI antibody coated magnetic beads can effectively improve the stability of the cTnI antibody coated magnetic beads in the storage and use processes, and protective agents such as sugar, alcohol, lipid and the like are not required to be added; in particular, the addition of the protective agent can significantly improve the stability, sensitivity and linear gradient of the reagent. And the preservation solution of the cTnI antibody coated magnetic beads has the advantages of simple components, simple and convenient preparation, low cost and convenient realization of mass production.
Drawings
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings that are required to be used in the embodiments or the description of the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments described in the present application, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph showing the results of a dose response curve test in an embodiment of the present invention;
Detailed Description
In order to better understand the technical solutions in the present application, the following description will clearly and completely describe the technical solutions in the embodiments of the present application with reference to the drawings in the embodiments of the present application, and it is obvious that the described embodiments are only some embodiments of the present application, not all embodiments. All other embodiments, which can be made by one of ordinary skill in the art based on the embodiments herein without making any inventive effort, shall fall within the scope of the present application.
It will be understood that when an element is referred to as being "fixed" or "disposed" on another element, it can be directly on the other element or be indirectly on the other element; when an element is referred to as being "connected to" another element, it can be directly connected to the other element or be indirectly connected to the other element.
It is to be understood that the terms "length," "width," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," and the like indicate or are based on the orientation or positional relationship shown in the drawings, merely to facilitate description of the present application and simplify description, and do not indicate or imply that the devices or elements referred to must have a particular orientation, be configured and operated in a particular orientation, and therefore should not be construed as limiting the present application.
Furthermore, the terms "first," "second," and the like, are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defining "a first" or "a second" may explicitly or implicitly include one or more such feature. In the description of the present application, the meaning of "a plurality" or "a number" is two or more, unless explicitly defined otherwise.
It should be understood that the structures, proportions, sizes, etc. shown in the drawings are for illustration purposes only and should not be construed as limiting the scope of the present disclosure, since any structural modifications, proportional changes, or dimensional adjustments made by those skilled in the art should not be made in the present disclosure without affecting the efficacy or achievement of the present disclosure.
The embodiment of the application is written in a progressive manner.
Example 1
A preservation solution of cTnI antibody coated magnetic beads, the solvent being pure water, comprising:
buffer salt: tris 50mmol/L;
protein: bovine serum albumin 10g/L;
and (2) a surfactant: triton x-100 g/L;
inorganic salts including sodium chloride: 0.15mol/L; magnesium chloride: 5.00mmol/L; zinc chloride: 0.10mmol/L;
and (3) a protective agent: cetostearyl alcohol polyether-25 g/L;
preservative: 1g/L of sodium azide and 300 g/L of PC;
the pH of the preservation solution was 7.4.
The preparation method of the preservation solution of the cTnI antibody coated magnetic beads comprises the following steps:
adding buffer salt into water, and uniformly mixing;
adding inorganic salt into water, and uniformly mixing;
adding protein into water, and uniformly mixing;
adding a surfactant into water, and uniformly mixing;
adding a protective agent into water, and uniformly mixing;
adding preservative into water and uniformly mixing;
adjusting the pH to 7.40+/-0.05;
constant volume, and filtering with 0.22um filter element.
The protectant added in the above examples is cetostearyl alcohol polyether-25, cremophor A25; the protective agent added in the subsequent examples was cetostearyl alcohol polyether-25 (Cremophor A25).
Example 2
A preservation solution of cTnI antibody coated magnetic beads, the solvent being pure water, comprising:
buffer salt: tris 50mmol/L;
protein: bovine serum albumin 15g/L;
and (2) a surfactant: triton x-100 g/L;
inorganic salts including sodium chloride: 0.15mol/L; magnesium chloride: 2.50mmol/L; zinc chloride: 0.50mmol/L;
and (3) a protective agent: cetostearyl alcohol polyether-25.10 g/L;
preservative: 1g/L of sodium azide and 300 g/L of PC;
the pH of the preservation solution was 7.4.
The preparation method of the preservation solution of the cTnI antibody coated magnetic beads comprises the following steps:
adding buffer salt into water, and uniformly mixing;
adding protein into water, and uniformly mixing; adding inorganic salt into water, and uniformly mixing;
adding a surfactant into water, and uniformly mixing;
adding a protective agent into water, and uniformly mixing;
adding preservative into water and uniformly mixing;
adjusting the pH to 7.40+/-0.05;
constant volume, and filtering with 0.22um filter element.
Example 3
A preservation solution of cTnI antibody coated magnetic beads, the solvent being pure water, comprising:
buffer salt: tris 50mmol/L;
protein: bovine serum albumin 10g/L;
and (2) a surfactant: triton x-100 g/L;
inorganic salts including sodium chloride: 0.15mmol/L; magnesium chloride: 2.50mmol/L; zinc chloride: 0.50mmol/L;
and (3) a protective agent: cetostearyl alcohol polyether-25 g/L;
preservative: 1g/L of sodium azide and 300 g/L of PC;
the pH of the preservation solution was 7.4.
The preparation method of the preservation solution of the cTnI antibody coated magnetic beads comprises the following steps:
adding buffer salt into water, and uniformly mixing;
adding a surfactant into water, and uniformly mixing;
adding a protective agent into water, and uniformly mixing;
adding inorganic salt into water, and uniformly mixing;
adding protein into water, and uniformly mixing;
adding preservative into water and uniformly mixing;
adjusting the pH to 7.40+/-0.05;
constant volume, and filtering with 0.22um filter element.
Comparative example 1
A preservation solution of cTnI antibody coated magnetic beads, the solvent being pure water, comprising:
buffer salt: tris 50mmol/L;
protein: bovine serum albumin 10g/L;
and (2) a surfactant: triton x-100 g/L;
inorganic salts including sodium chloride: 0.15mol/L; magnesium chloride: 2.50mmol/L; zinc chloride: 0.50mmol/L;
preservative: 1g/L of sodium azide and 300 g/L of PC;
the pH of the preservation solution was 7.4.
The preparation method of the preservation solution of the cTnI antibody coated magnetic beads comprises the following steps:
adding buffer salt into water, and uniformly mixing;
adding inorganic salt into water, and uniformly mixing;
adding protein into water, and uniformly mixing;
adding a surfactant into water, and uniformly mixing;
adding preservative into water and uniformly mixing;
adjusting the pH to 7.40+/-0.05;
constant volume, and filtering with 0.22um filter element.
Comparative example 2
A preservation solution of cTnI antibody coated magnetic beads, the solvent being pure water, comprising:
buffer salt: tris 50mmol/L;
protein: bovine serum albumin 10g/L;
and (2) a surfactant: triton x-100 g/L;
inorganic salts including sodium chloride: 0.15mol/L; magnesium chloride: 2.50mmol/L; zinc chloride: 0.50mmol/L;
preservative: 1g/L of sodium azide and 300 g/L of PC;
and (3) a protective agent: glycerin 50g/L, sucrose 10g/L, polyethylene glycol 4000 1g/L;
the pH of the preservation solution was 7.4.
The preparation method of the preservation solution of the cTnI antibody coated magnetic beads comprises the following steps:
adding buffer salt into water, and uniformly mixing;
adding inorganic salt into water, and uniformly mixing;
adding protein into water, and uniformly mixing;
adding a surfactant into water, and uniformly mixing;
adding a protective agent into water, and uniformly mixing;
adding preservative into water and uniformly mixing;
adjusting the pH to 7.40+/-0.05;
constant volume, and filtering with 0.22um filter element.
Comparative example 3
A preservation solution of cTnI antibody coated magnetic beads, the solvent being pure water, comprising:
buffer salt: tris 50mmol/L;
protein: bovine serum albumin 10g/L;
and (2) a surfactant: triton x-100 g/L;
inorganic salts including sodium chloride: 0.15mol/L; magnesium chloride: 2.50mmol/L; zinc chloride: 0.50mmol/L;
and (3) a protective agent: cetostearyl alcohol polyether-25.5 g/L;
preservative: 1g/L of sodium azide and 300 g/L of PC;
the pH of the preservation solution was 7.4.
The preparation method of the preservation solution of the cTnI antibody coated magnetic beads comprises the following steps:
adding buffer salt into water, and uniformly mixing;
adding inorganic salt into water, and uniformly mixing;
adding protein into water, and uniformly mixing;
adding a surfactant into water, and uniformly mixing;
adding a protective agent into water, and uniformly mixing;
adding preservative into water and uniformly mixing;
adjusting the pH to 7.40+/-0.05;
constant volume, filtering with 0.22um filter element
Comparative example 4
A preservation solution of cTnI antibody coated magnetic beads, the solvent being pure water, comprising:
buffer salt: tris 50mmol/L;
protein: bovine serum albumin 10g/L;
and (2) a surfactant: triton x-100 g/L;
inorganic salts including sodium chloride: 0.15mol/L; magnesium chloride: 2.50mol/L; zinc chloride: 0.50mol/L;
and (3) a protective agent: cetostearyl alcohol polyether-25 g/L;
preservative: 1g/L of sodium azide and 300 g/L of PC;
the pH of the preservation solution was 7.4.
The preparation method of the preservation solution of the cTnI antibody coated magnetic beads comprises the following steps:
adding buffer salt into water, and uniformly mixing;
adding inorganic salt into water, and uniformly mixing;
adding protein into water, and uniformly mixing;
adding a surfactant into water, and uniformly mixing;
adding a protective agent into water, and uniformly mixing;
adding preservative into water and uniformly mixing;
adjusting the pH to 7.40+/-0.05;
constant volume, filtering with 0.22um filter element
The preservation solutions of the cTnI antibody-coated magnetic beads of examples 1 to 3 and comparative examples 1 to 4 were tested.
Experiment one: stability verification
The magnetic bead reagent is prepared by adding cTnI antibody coated magnetic bead mother liquor into the preservation solution.
The reagent is divided into 2 parts, one part is placed at 37 ℃ and aged for 7 days, and the other part is placed at 2-8 ℃ and stored. After 7 days of standing, the same samples were tested simultaneously with two reagents using the reagent at 2-8deg.C as a control. The test results were as follows:
TABLE 1 stability test results
From the results of experimental examples 1-3, the working solution obtained by diluting the cTnI antibody coated magnetic beads with the preservation solution is accelerated for 7 days at 37 ℃, and the luminous value is reduced to be within 3.0%; the concentration of the cetostearyl alcohol polyether-25 is in the range of 1-10g/L, and has no obvious influence on stability. As is clear from comparative example 1, the luminous value without the addition of the protective agent was reduced by 20.0% or more. As is clear from comparative example 2, the preservation solution was added with a protective agent such as an alcohol, a saccharide, or a polymer, and the luminescence value was reduced by about 15.0%. As can be seen from comparative examples 3-4, too much or too little cetostearyl alcohol polyether-25 concentration affects reagent stability.
Experiment II: sensitivity verification
The magnetic bead reagent is prepared by adding cTnI antibody coated magnetic bead mother liquor into the preservation solution, and the cTnI reagent is formed by matching with an enzyme marker, a 0 concentration sample is tested for 20 times, a blank limit is calculated, and the test result is as follows:
TABLE 2 sensitivity test results
From the results of experimental examples 1 to 3, the working solution obtained by diluting cTnI antibody-coated magnetic beads with the preservation solution of the present invention had a blank of 0.002. As is clear from comparative examples 1 to 2, no addition of cetostearyl alcohol polyether-25 protecting agent or other protecting agents such as alcohols, saccharides and polymers has a large influence on the blank space. As can be seen from comparative examples 3-4, too much or too little cetostearyl alcohol polyether-25 concentration is detrimental to blank testing.
The concentrations of examples 1-3 and comparative examples 1-4 were plotted against RLU to give dose response curves as shown in figure 1.
Experiment III: linear gradient validation
The magnetic bead reagent is prepared by adding cTnI antibody coated magnetic bead mother liquor into the preservation solution, and the cTnI reagent is formed by matching with an enzyme marker, and linear gradient test is carried out, and the test result is as follows:
TABLE 3 Linear gradient test results
From the results of experimental examples 1-3, the working solution obtained by diluting the cTnI antibody coated magnetic beads with the preservation solution provided by the invention has obvious linear gradient and obvious rising trend within the range of 0-50 ng/mL. As is clear from comparative examples 1-2, the linear gradient was significantly reduced without addition of the cetostearyl alcohol polyether-25 protectant or with addition of other protectants such as alcohols, saccharides, polymers, etc. As can be seen from comparative examples 3-4, too much or too little of cetostearyl alcohol polyether-25 concentration is detrimental to the linear gradient test.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (8)
1. The preservation solution of the cTnI antibody coated magnetic beads is characterized by comprising the following components:
20-100mmol/L of buffer salt;
2-20g/L of protein;
0.5-5g/L of surfactant;
0.1 to 0.5mol/L of inorganic salt;
the protective agent is cetostearyl alcohol polyether-25-10 g/L;
0.5-5g/L preservative;
the pH value of the preservation solution is 7.0-8.0;
the buffer salt is specifically any one of Tris, MES, MOPS, HEPES;
the protein is specifically any one or more of bovine serum albumin, casein and gelatin protein;
the surfactant is one or more of triton x-100, triton x-405, tween 20 and Tween 80;
the inorganic salt is a combination of sodium chloride, magnesium chloride and zinc chloride; or, a combination of potassium chloride, magnesium chloride and zinc chloride;
the preservation solution does not need sugar, alcohol or lipid protectant.
2. The preservation solution of cTnI antibody-coated magnetic beads according to claim 1,
the concentration of the buffer salt is 50-60mmol/L.
3. The preservative solution for cTnI antibody-coated magnetic beads according to claim 1, wherein the protein is bovine serum albumin, and the concentration of bovine serum albumin is 10-15g/L.
4. The preservation solution of cTnI antibody-coated magnetic beads according to claim 1,
the concentration of the surfactant is 1-2g/L.
5. The preservation solution of cTnI antibody coated magnetic beads according to claim 1, wherein the concentration of sodium chloride in the inorganic salt composition is 0.1 to 0.3mol/L; the concentration of magnesium chloride is 0.5-5mmol/L; the concentration of zinc chloride is 0.05-1mmol/L; the concentration of potassium chloride is 0.1-0.3 mol/L.
6. The preservation solution of cTnI antibody-coated magnetic beads according to claim 5, wherein the concentration of sodium chloride in the inorganic salt composition is 0.1 to 0.2mol/L; the concentration of magnesium chloride is 2.5-5 mmol/L; zinc chloride is 0.1-0.5 mmol/L; the concentration of potassium chloride is 0.1-0.2 mol/L.
7. The preservation solution of cTnI antibody-coated magnetic beads according to claim 1, wherein the preservative is specifically any one or more of sodium azide, PC300, chloramphenicol, and gentamicin; and/or the number of the groups of groups,
the concentration of the preservative is 1-2g/L.
8. A method for preparing a preservation solution of cTnI antibody-coated magnetic beads according to claim 1, comprising the steps of:
respectively adding buffer salt, protein, surfactant, inorganic salt, cetostearyl alcohol polyether-25 serving as a protective agent and preservative into water, and uniformly mixing to ensure that the concentration of the buffer salt is 20-100mmol/L and the concentration of the protein is 2-20g/L; the concentration of the surfactant is 0.5-5g/L; the concentration of the inorganic salt is 0.1-0.5mol/L; the concentration of the protecting agent cetostearyl alcohol polyether-25 is 1-10g/L, and the concentration of the preservative is 0.5-5g/L; and adjusting the pH to 7.0-8.0;
constant volume and filtering.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110905348.5A CN113607962B (en) | 2021-08-06 | 2021-08-06 | Preservation solution for cTnI antibody coated magnetic beads and preparation method thereof |
| PCT/CN2021/117122 WO2023010647A1 (en) | 2021-08-06 | 2021-09-08 | Ctni antibody-coated magnetic bead preservation solution and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110905348.5A CN113607962B (en) | 2021-08-06 | 2021-08-06 | Preservation solution for cTnI antibody coated magnetic beads and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113607962A CN113607962A (en) | 2021-11-05 |
| CN113607962B true CN113607962B (en) | 2023-05-09 |
Family
ID=78339845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110905348.5A Active CN113607962B (en) | 2021-08-06 | 2021-08-06 | Preservation solution for cTnI antibody coated magnetic beads and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113607962B (en) |
| WO (1) | WO2023010647A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115684581A (en) * | 2021-07-28 | 2023-02-03 | 北京京东方技术开发有限公司 | Preservation solution of magnetic beads and preservation method thereof |
| CN115047185A (en) * | 2022-06-08 | 2022-09-13 | 国家粮食和物资储备局科学研究院 | Preserving fluid of immunoaffinity material and application thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0535485B1 (en) * | 1991-10-03 | 1997-07-16 | Bayer Corporation | Device and method of separating and assaying whole blood |
| SK53294A3 (en) * | 1993-05-07 | 1995-04-12 | Albright & Wilson | Concentrated aqueous mixture containing surface active matter and its use |
| US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
| GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| CN102426246A (en) * | 2011-08-31 | 2012-04-25 | 内蒙古科慧生物科技有限责任公司 | Human troponin I quantitative determination kit and detection method thereof |
| EP4215898A1 (en) * | 2015-04-20 | 2023-07-26 | Ventana Medical Systems, Inc. | Inkjet deposition of reagents for histological samples |
| CN108375571B (en) * | 2018-02-05 | 2019-11-26 | 苏州长光华医生物医学工程有限公司 | A kind of magnetic particle reagents and kit for chemiluminescence immunoassay detection |
| CN108333370A (en) * | 2018-02-09 | 2018-07-27 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects cTnI kits |
| CN109061189A (en) * | 2018-08-17 | 2018-12-21 | 深圳天辰医疗科技有限公司 | A kind of Troponin I detection kit and preparation method thereof |
| CN109646374A (en) * | 2019-01-21 | 2019-04-19 | 秋臣化妆品有限公司 | A kind of herbal mildy wash and preparation method of moisturizing whitening |
| CN109709323A (en) * | 2019-02-15 | 2019-05-03 | 深圳上泰生物工程有限公司 | High quick cardiac muscle troponin I magnetic microparticle chemiluminescence immunity detection reagent, Preparation method and use |
| CN112526140A (en) * | 2020-11-16 | 2021-03-19 | 北京利德曼生化股份有限公司 | Magnetic particle chemiluminescence detection kit for determining content of hypersensitive troponin T |
| CN112698023B (en) * | 2020-12-01 | 2023-12-15 | 三诺生物传感股份有限公司 | Preservation solution of alkaline phosphatase-labeled conjugate and preparation method thereof |
-
2021
- 2021-08-06 CN CN202110905348.5A patent/CN113607962B/en active Active
- 2021-09-08 WO PCT/CN2021/117122 patent/WO2023010647A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN113607962A (en) | 2021-11-05 |
| WO2023010647A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113607962B (en) | Preservation solution for cTnI antibody coated magnetic beads and preparation method thereof | |
| CN112730839B (en) | Kit for measuring content of cytokeratin 19 fragments by magnetic particle chemiluminescence method | |
| DE68925603T2 (en) | Acridinium esters and method for the detection of analyte with acridinium esters and liposomes | |
| US4649123A (en) | Ion test means having a hydrophilic carrier matrix | |
| CN109187973B (en) | Chemiluminescence immunoassay kit for detecting neuron specific enolase | |
| AU570522B2 (en) | Stabilization of indicators for detecting enzyme activity | |
| CN112698023B (en) | Preservation solution of alkaline phosphatase-labeled conjugate and preparation method thereof | |
| Wrigley et al. | Human erythrocyte glucose 6-phosphate dehydrogenase: electron microscope studies on structure and interconversion of tetramers, dimers and monomers | |
| Green et al. | A preliminary crystallographic investigation of avidin | |
| DE3311889A1 (en) | METHOD FOR IRREVERSIBLE BINDING OF PROTEIN TO POLYSTYROL SURFACES WITH THE PRESERVATION OF BIOLOGICAL ACTIVITY, POLYSTYROL SURFACES OBTAINED AND THEIR USE | |
| Samaržija et al. | Electrophysiological analysis of rat renal sugar and amino acid transport: III. Neutral amino acids | |
| US4486531A (en) | Method and reagent for the determination of β-lipoprotein | |
| US12180183B2 (en) | Water-soluble fluorescent probe and nanoparticals with aggregation-induced emission effect for ovarian cancer and preparation method and use thereof | |
| WO2023142398A1 (en) | Coronavirus rbd protein-fluorescent microsphere complex preparation | |
| Penniston | Fluorescence polarization measurement of binding of fluorescein to albumin | |
| US20200408787A1 (en) | Stabilized quality control materials for red blood cells for diagnostic tests | |
| CN112268868A (en) | Kit for determining calprotectin by latex immunoturbidimetry | |
| Breyer et al. | The adsorptive capacity of serum proteins in renal insufficiency. | |
| CN117849359A (en) | Heart type fatty acid binding protein control product and preparation and application thereof | |
| CN113702647B (en) | Human growth differentiation factor 15 instant detection kit, preparation method and application thereof | |
| CN116413253A (en) | Human papilloma virus detection reagent and application thereof | |
| CN114966055A (en) | Application of buffer solution in detection kit for acidic protein in glial fibers | |
| CN114965990A (en) | Calibrator buffer for detecting Tn antigen on surface of carbohydrate antigen CA125, preparation method thereof and detection kit | |
| US5589327A (en) | Method and composition for the determination of red blood cell floate | |
| CN112730834A (en) | Neuron-specific enolase (NSE) determination kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |